The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy
KANECT
1 other identifier
interventional
40
1 country
1
Brief Summary
The main aim of this research is to ascertain whether Ketamine would be a more effective anaesthetic for Electroconvulsive Therapy (ECT) than the standard anaesthetic. In doing so the investigators aim to examine the effect of ketamine on ratings of depressive symptoms, the number of required ECT treatments, and the effect of this anaesthetic on memory.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4 depression
Started Mar 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 1, 2011
CompletedStudy Start
First participant enrolled
March 1, 2011
CompletedFirst Posted
Study publicly available on registry
March 2, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2014
CompletedSeptember 8, 2016
September 1, 2016
2.9 years
March 1, 2011
September 7, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in depressive symptoms
The primary outcome measure will be change in depressive symptoms after the fourth ECT treatment. This will be assessed by the change in MADRS and 17-item HDRS scores between start of treatment and this timepoint.
After 4th treatment
Secondary Outcomes (2)
Cognitive side-effects
2 months
Change in depressive symptoms after treatment
2 months
Study Arms (2)
Ketamine
EXPERIMENTALKetamine used as the anaesthetic during ECT.
Propofol
ACTIVE COMPARATORPropofol, the standard anaesthetic, used during ECT.
Interventions
Eligibility Criteria
You may qualify if:
- between the ages of 18 and 65 years old
- diagnosed with depression and being referred for ECT
- American Society of Anesthesiologists (ASA) score of 1 or 2
- patient receiving ECT on an informal basis (i.e. consenting to treatment and able to give informed consent)
You may not qualify if:
- pre-existing neurological disease or cognitive impairment
- co-morbid psychiatric diagnoses
- pre-existing hypertension
- severe respiratory tract disease
- major cardiovascular disease
- pacemakers
- cerebrovascular disorder or malformation
- intracranial mass lesions
- seizure disorder
- intracranial electrode or clips
- intra-ocular pathology
- endocrine or metabolic disease
- severe hematologic disease
- severe fracture
- not able to give consent
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Aberdeenlead
- NHS Grampiancollaborator
- Chief Scientist Office of the Scottish Governmentcollaborator
Study Sites (1)
Royal Cornhill Hospital, NHS Grampian
Aberdeen, AB25 2ZH, United Kingdom
Related Publications (1)
Fernie G, Currie J, Perrin JS, Stewart CA, Anderson V, Bennett DM, Hay S, Reid IC. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial. Br J Psychiatry. 2017 Jun;210(6):422-428. doi: 10.1192/bjp.bp.116.189134. Epub 2017 Mar 2.
PMID: 28254962DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ian C Reid, PhD
University of Aberdeen
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 1, 2011
First Posted
March 2, 2011
Study Start
March 1, 2011
Primary Completion
February 1, 2014
Study Completion
February 1, 2014
Last Updated
September 8, 2016
Record last verified: 2016-09